After finding several errors in their paper about the molecular activity underlying gastric cancer, the authors unanimously decided to retract it.
According to the retraction note, three figures in the paper had β‑actin bands that were omitted, interchanged, or both.
The retraction note provides the details:
Continue reading Upon discovering several errors, authors retract gastric cancer paper
A 2006 paper investigating the effects of docosahexaenoic acid (DHA) and celecoxib on prostate cancer cells has been retracted because it appears to contain panels that were duplicated, and the authors could not provide the raw data to show otherwise.
This is the second paper the authors have lost because they couldn’t furnish the original data to defend their work against allegations of image manipulation. The reason: the Institute for Cancer Prevention in New York, where the authors did the work, shut its doors abruptly in 2004, co-author Bhagavathi A. Narayanan told us. (The institute closed thanks to $5.7 million in grant that was misspent, the New York Post reported at the time.)
Recently, some of Narayanan’s papers have been questioned on PubPeer; her work has been the subject of an investigation at New York University, where Narayanan is now based.
Narayanan told us that the criticism of their work has deeply affected her and her co-authors:
Continue reading “We are living in hell:” Authors retract 2nd paper due to missing raw data
An MD Anderson Cancer Center researcher who has been under investigation by the institution for at least several years has had seven papers retracted from a single journal.
Bharat Aggarwal told us in 2012 that MD Anderson was investigating his work, but in 2013 threatened to sue us for reporting on the case. Aggarwal is no longer listed in the MD Anderson directory, and an email to him there bounced.
This week, Biochemical Pharmacology retracted seven studies of which he is the only common author, noting the “data integrity has become questionable.” The papers have been cited a total of more than 500 times, according to Thomson Scientific’s Web of Knowledge; one has been designated as “highly cited.” Here are the seven retractions: Continue reading Journal retracts 7 papers by MD Anderson cancer researcher long under investigation
A Toronto hospital network is keeping two researchers’ labs closed even after an Ontario court quashed part of a misconduct finding by the institution.
Some background: After the University Health Network found evidence of falsified data, Sylvia Asa stepped down as Program Medical Director of the Laboratory Medicine Program, the largest hospital diagnostic laboratory in Canada. Due to the investigation, UHN suspended the labs of Asa and her husband Shereen Ezzat. In response, Asa and Ezzat asked an Ontario court to quash the misconduct findings; last month, the court overturned two out of three findings, and asked UHN to reconsider its sanction against the pair.
According to the Toronto Star, on February 4th the UHN notified the researchers that the sanction against them would be upheld, and it would not reopen the researchers’ labs.
The Star spoke to the researcher’s lawyer, Brian Moher who Continue reading Sanction for Toronto researchers upheld despite court challenge
A journal is Journals are retracting three papers after a biomaterials researcher duplicated his own work, sometimes using the same figures to describe different experiments.
Two of the papers are on bone regeneration; one is about targeting tumors. In addition to issues with figures, two one of the retraction notes explain that the papers contain “widespread plagiarism of text” from other papers by the researcher, Hossein Hosseinkhani.
Hosseinkhani is currently affiliated with the National Taiwan University of Science and Technology; when he did the work in the now retracted papers, published in 2004 and 2007, he was based at Kyoto University Hospital and then National Institute for Materials Science in Japan.
The Journal of Controlled Release published all three two of the papers. Here’s the retraction note for “Bone regeneration through controlled release of bone morphogenetic protein-2 from 3-D tissue engineered nano-scaffold,” which has been cited 118 times, according to Thomson Scientific’s Web of Knowledge.
Continue reading Journals retracts three bone papers for duplication by same author
A paper on nanoparticles that target cancer cells has been retracted for duplicating figures from three other papers.
The articles all share a first author: Manasmita Das, based at the time of the research at the Indian Institute of Technology Kharagpur and the National Institute of Pharmaceutical Education and Research (NIPER). According to her LinkedIn profile, she is currently a postdoc at the University of North Carolina.
The abstract of the 2011 Bioconjugate Chemistry paper explains just what the new nanoparticles would be useful for:
Multifunctional nanoparticles, developed in the course of the study, could selectively target and induce apoptosis to folate-receptor (FR) overexpressing cancer cells with enhanced efficacy as compared to the free drug. In addition, the dual optical and magnetic properties of the synthesized nanoparticles aided in the real-time tracking of their intracellular pathways also as apoptotic events through dual fluorescence and MR-based imaging.
But according to the retraction note, figure duplications “seriously undermine the conclusions presented in the research article.” Here’s more about the source of those duplications from the full note: Continue reading Journal retracts nanoparticles paper for duplicating figures
A paper flagged in an Office of Research Integrity notice more than one year ago has finally been retracted. According to the notice, the paper includes images manipulated by author H. Rosie Xing, a former University of Chicago cancer researcher.
The main conclusions of the paper are affected by the ORI finding, according to the retraction note from Molecular Cancer Therapeutics. But otherwise, the note contains information that was available in the ORI finding, published in December 2014.
“Pharmacologic Inactivation of Kinase Suppressor of Ras1 Sensitizes Epidermal Growth Factor Receptor and Oncogenic Ras-Dependent Tumors to Ionizing Radiation Treatment” has been cited seven times, according to Thomson Scientific’s Web of Knowledge — twice since the ORI finding came out.
The retraction note explains which images were affected by the manipulation:
Continue reading 2014 ORI finding results in retraction of cancer paper with manipulated images
An investigation at the University of New South Wales in Australia has led to a fifth retraction for a cancer researcher long accused of misconduct, due to “unresolvable concerns” with some images.
As we reported in December, UNSW cleared Levon Khachigian of misconduct, concluding that his previous issues stemmed from “genuine error or honest oversight.” Now, Circulation Research is retracting one of his papers after an investigation commissioned by UNSW was unable to find electronic records for two similar images from a 2009 paper, nor records of the images in original lab books.
Again, the retraction note affirms that this is not a sign of misconduct:
UNSW has not attributed any instance of research misconduct or responsibility for the unavailability of the original data to Professor Khachigian or to any of the authors of the publication.
Here’s the retraction note in full for “Angiotensin II-Inducible Smooth Muscle Cell Apoptosis Involves the Angiotensin II Type 2 Receptor, GATA-6 Activation, and FasL-Fas Engagement:” Continue reading Investigation prompts 5th retraction for cancer researcher for “unresolvable concerns”
Remember when we recently found PLOS ONE had published two papers with “substantial overlap” from two different groups, that were edited around the same time? Well, we have discovered another similarly perplexing case of plagiarism in two studies published only months apart. But in this instance, we have a possible explanation for how two groups of authors from different institutions could report a similar experiment and data, and even use some of the same text.
It also concerns a paper focusing on cancer biology — in this case, it’s a 2014 paper retracted by Clinical and Investigative Medicine after editors learned that it contained many similarities to a study published only a handful of months before in Tumour Biology.
According to an email from an author on the retracted paper to the editor, Continue reading Another case of plagiarism in papers published only months apart
A recent recipient of an early career award now under investigation by granting agency EMBO told us today that last week’s retraction in Nature Genetics stemmed solely from an “embarrassing error,” and she hopes to republish the data in a new paper.
Last week was rough for Sonia Melo: Nature Genetics retracted one of her papers, and the European Molecular Biology Organization (EMBO) announced it was investigating the papers that formed the basis of her application. The retraction was of “A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function,” which has been cited 235 times, according to Thomson Scientific’s Web of Knowledge.
Melo’s Installation Grant from EMBO was announced in December, and consists of 50,000 Euros annually for three to five years. She is currently based at the University of Porto, in Portugal.
Melo contacted us today to defend her record: Continue reading “There was no effort to commit fraud,” says EMBO awardee under investigation